Skip to content

Mary M Torregrossa

2 papers in the library · 3 citations · publishing 2025-2026

Papers

Sex specific effects of ketamine, but not other glutamate receptor modulators, on ethanol self-administration and reinstatement of ethanol seeking in rats.

Psychopharmacology April 8, 2025 Megan L Bertholomey, Camryn Forbes, Bryan D McElroy et al. 3 citations

Ketamine reduces alcohol seeking in female but not male rats, including in a model of stress combined with cues that trigger relapse. A dose of 10 mg/kg ketamine selectively lowered alcohol self-administration and stress-plus-cue-induced reinstatement of alcohol seeking in females. The same dose reduced reinstatement of saccharin seeking in both sexes. The NMDA receptor antagonist memantine reduced alcohol seeking in both sexes, while the ketamine metabolite hydroxynorketamine had no effect. These findings suggest that NMDA receptor antagonism may broadly reduce stress-related alcohol seeking, but ketamine has unique properties producing female-specific effects on alcohol-motivated behaviors.

Envisioning Cannabinoid CB1 Receptor Biased Signaling as a Therapeutic Target for Schizophrenia.

The American journal of psychiatry April 17, 2026 Shih-Hsuan Ku, Sierra J Stringfield, Mary M Torregrossa et al.

Cannabis use is more common among people with schizophrenia than the general population, partly due to shared genetic risk. Beyond overlapping risks, cannabis pharmacologically worsens an already altered cortical system. Cannabis use dose-dependently increases the likelihood of a schizophrenia diagnosis, acutely worsens symptoms, and leads to poorer long-term outcomes. The psychoactive component, Δ9-tetrahydrocannabinol, acts on the cannabinoid CB1 receptor (CB1R), a G protein-coupled receptor. This review examines recent advances in understanding CB1R biology, sex differences, alterations in schizophrenia, and the impact of comorbid cannabis use. Cell type-specific findings reconcile past discrepancies, and new knowledge of GPCR pharmacology and biased ligands offers opportunities for CB1R-targeted therapeutics for schizophrenia, especially with comorbid cannabis use.